MediGene (ETR:MDG1) has been given a €22.00 ($27.16) price objective by equities researchers at Baader Bank in a report issued on Monday. The brokerage presently has a “buy” rating on the stock. Baader Bank’s target price points to a potential upside of 60.94% from the stock’s current price.
Other research analysts also recently issued research reports about the stock. Oddo Bhf set a €13.00 ($16.05) price objective on shares of MediGene and gave the stock a “neutral” rating in a research report on Friday, March 23rd. Independent Research set a €16.50 ($20.37) price objective on shares of MediGene and gave the stock a “neutral” rating in a research report on Thursday, March 22nd.
ETR MDG1 traded up €0.07 ($0.09) on Monday, hitting €13.75 ($16.98). 69,807 shares of the company’s stock traded hands, compared to its average volume of 306,207. MediGene has a 1-year low of €8.53 ($10.53) and a 1-year high of €19.27 ($23.79).
MediGene Company Profile
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.